Drugs / Syntocinon-Spray
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01938911 | Nov 2014 → Jun 2016 | essential hypertension | Insel Gruppe AG, University Hospital Bern | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Syntocinon-Spray | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01938911 ↗ |
| Modality | Peptide | “neuropeptide oxytocin” NCT01938911 ↗ |
| Route | Intranasal | “Intranasal oxytocin (24 IU)” NCT01938911 ↗ |